Skip to main content
Erschienen in: Breast Cancer Research and Treatment 3/2017

23.08.2017 | Epidemiology

Familial associations of male breast cancer with other cancers

verfasst von: Guoqiao Zheng, Hongyao Yu, Akseli Hemminki, Asta Försti, Kristina Sundquist, Kari Hemminki

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Male breast cancer is associated with female breast cancer in families but whether male breast cancer clusters with other discordant cancers has not been studied. As concordant male breast cancers are utterly rare, discordant associations of male breast cancer with other cancers may reveal genetic and possible environmental risk factors contributing to male breast cancer susceptibility.

Methods

We calculated relative risks (RRs) for male breast cancer in families with discordant cancers, and conversely, for discordant cancers in families of male breast cancer patients, based on 15.7 million individuals in the Swedish Family-Cancer Database.

Results

Among 1428 male breast cancer patients, 16.2% had a female relative diagnosed with breast cancer. Ovarian and female anal cancers showed the strongest associations with male breast cancer (p value < 0.0005). The other significant associations included colorectal, small intestinal, and thyroid cancers, cancer of unknown primary and non-Hodgkin lymphoma but these were each based on a single positive association with male breast cancer. The RRs for male breast cancer were increased in families in which multiple patients were diagnosed with diverse cancers, reaching an RR of 2.58 when three or more family members were affected.

Conclusions

The results suggest that male breast cancer shares susceptibility with a number of other cancers but confirmation is needed in other datasets.
Literatur
1.
Zurück zum Zitat Rosenblatt KA, Thomas DB, McTiernan A, Austin MA, Stalsberg H, Stemhagen A, Thompson WD, Curnen MG, Satariano W, Austin DF et al (1991) Breast cancer in men: aspects of familial aggregation. J Natl Cancer Inst 83(12):849–854CrossRefPubMed Rosenblatt KA, Thomas DB, McTiernan A, Austin MA, Stalsberg H, Stemhagen A, Thompson WD, Curnen MG, Satariano W, Austin DF et al (1991) Breast cancer in men: aspects of familial aggregation. J Natl Cancer Inst 83(12):849–854CrossRefPubMed
2.
Zurück zum Zitat Anderson D, Badzioch M (1991) Breast cancer risks in relatives of male breast cancer patients. J Natl Cancer Inst 84:1114–1117CrossRef Anderson D, Badzioch M (1991) Breast cancer risks in relatives of male breast cancer patients. J Natl Cancer Inst 84:1114–1117CrossRef
4.
Zurück zum Zitat Dong C, Hemminki K (2001) Second primary breast cancer in men. Breast Cancer Res Treat 66:171–172CrossRefPubMed Dong C, Hemminki K (2001) Second primary breast cancer in men. Breast Cancer Res Treat 66:171–172CrossRefPubMed
5.
Zurück zum Zitat Hemminki K, Granstrom C (2002) Re: risk of subsequent cancer following breast cancer in men. J Natl Cancer Inst 94:1892CrossRefPubMed Hemminki K, Granstrom C (2002) Re: risk of subsequent cancer following breast cancer in men. J Natl Cancer Inst 94:1892CrossRefPubMed
6.
Zurück zum Zitat Hemminki K, Scelo G, Boffetta P, Mellemkjaer L, Tracey E, Andersen A, Brewster DH, Pukkala E, McBride M, Kliewer EV, Chia KS, Pompe-Kirn V, Martos C, Jonasson JG, Li X, Brennan P (2005) Second primary malignancies in patients with male breast cancer. Br J Cancer 92:1288–1292CrossRefPubMedPubMedCentral Hemminki K, Scelo G, Boffetta P, Mellemkjaer L, Tracey E, Andersen A, Brewster DH, Pukkala E, McBride M, Kliewer EV, Chia KS, Pompe-Kirn V, Martos C, Jonasson JG, Li X, Brennan P (2005) Second primary malignancies in patients with male breast cancer. Br J Cancer 92:1288–1292CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Liede A, Karlan BY, Narod SA (2004) Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. J Clin Oncol 22:735–742CrossRefPubMed Liede A, Karlan BY, Narod SA (2004) Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. J Clin Oncol 22:735–742CrossRefPubMed
9.
Zurück zum Zitat Silvestri V, Barrowdale D, Mulligan AM, Neuhausen SL, Fox S, Karlan BY, Mitchell G, James P, Thull DL, Zorn KK, Carter NJ, Nathanson KL, Domchek SM, Rebbeck TR, Ramus SJ, Nussbaum RL, Olopade OI, Rantala J, Yoon SY, Caligo MA, Spugnesi L, Bojesen A, Pedersen IS, Thomassen M, Jensen UB, Toland AE, Senter L, Andrulis IL, Glendon G, Hulick PJ, Imyanitov EN, Greene MH, Mai PL, Singer CF, Rappaport-Fuerhauser C, Kramer G, Vijai J, Offit K, Robson M, Lincoln A, Jacobs L, Machackova E, Foretova L, Navratilova M, Vasickova P, Couch FJ, Hallberg E, Ruddy KJ, Sharma P, Kim SW, Teixeira MR, Pinto P, Montagna M, Matricardi L, Arason A, Johannsson OT, Barkardottir RB, Jakubowska A, Lubinski J, Izquierdo A, Pujana MA, Balmana J, Diez O, Ivady G, Papp J, Olah E, Kwong A, Nevanlinna H, Aittomaki K, Perez Segura P, Caldes T, Van Maerken T, Poppe B, Claes KB, Isaacs C, Elan C, Lasset C, Stoppa-Lyonnet D, Barjhoux L, Belotti M, Meindl A, Gehrig A, Sutter C, Engel C, Niederacher D, Steinemann D, Hahnen E, Kast K, Arnold N, Varon-Mateeva R, Wand D, Godwin AK, Evans DG, Frost D, Perkins J, Adlard J, Izatt L, Platte R, Eeles R, Ellis S, Hamann U, Garber J, Fostira F, Fountzilas G, Pasini B, Giannini G, Rizzolo P, Russo A, Cortesi L, Papi L, Varesco L, Palli D, Zanna I, Savarese A, Radice P, Manoukian S, Peissel B, Barile M, Bonanni B, Viel A, Pensotti V, Tommasi S, Peterlongo P, Weitzel JN, Osorio A, Benitez J, McGuffog L, Healey S, Gerdes AM, Ejlertsen B, Hansen TV, Steele L, Ding YC, Tung N, Janavicius R, Goldgar DE, Buys SS, Daly MB, Bane A, Terry MB, John EM, Southey M, Easton DF, Chenevix-Trench G, Antoniou AC, Ottini L (2016) Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the consortium of investigators of modifiers of BRCA1/2. Breast Cancer Res 18(1):15. doi:10.1186/s13058-016-0671-y CrossRefPubMedPubMedCentral Silvestri V, Barrowdale D, Mulligan AM, Neuhausen SL, Fox S, Karlan BY, Mitchell G, James P, Thull DL, Zorn KK, Carter NJ, Nathanson KL, Domchek SM, Rebbeck TR, Ramus SJ, Nussbaum RL, Olopade OI, Rantala J, Yoon SY, Caligo MA, Spugnesi L, Bojesen A, Pedersen IS, Thomassen M, Jensen UB, Toland AE, Senter L, Andrulis IL, Glendon G, Hulick PJ, Imyanitov EN, Greene MH, Mai PL, Singer CF, Rappaport-Fuerhauser C, Kramer G, Vijai J, Offit K, Robson M, Lincoln A, Jacobs L, Machackova E, Foretova L, Navratilova M, Vasickova P, Couch FJ, Hallberg E, Ruddy KJ, Sharma P, Kim SW, Teixeira MR, Pinto P, Montagna M, Matricardi L, Arason A, Johannsson OT, Barkardottir RB, Jakubowska A, Lubinski J, Izquierdo A, Pujana MA, Balmana J, Diez O, Ivady G, Papp J, Olah E, Kwong A, Nevanlinna H, Aittomaki K, Perez Segura P, Caldes T, Van Maerken T, Poppe B, Claes KB, Isaacs C, Elan C, Lasset C, Stoppa-Lyonnet D, Barjhoux L, Belotti M, Meindl A, Gehrig A, Sutter C, Engel C, Niederacher D, Steinemann D, Hahnen E, Kast K, Arnold N, Varon-Mateeva R, Wand D, Godwin AK, Evans DG, Frost D, Perkins J, Adlard J, Izatt L, Platte R, Eeles R, Ellis S, Hamann U, Garber J, Fostira F, Fountzilas G, Pasini B, Giannini G, Rizzolo P, Russo A, Cortesi L, Papi L, Varesco L, Palli D, Zanna I, Savarese A, Radice P, Manoukian S, Peissel B, Barile M, Bonanni B, Viel A, Pensotti V, Tommasi S, Peterlongo P, Weitzel JN, Osorio A, Benitez J, McGuffog L, Healey S, Gerdes AM, Ejlertsen B, Hansen TV, Steele L, Ding YC, Tung N, Janavicius R, Goldgar DE, Buys SS, Daly MB, Bane A, Terry MB, John EM, Southey M, Easton DF, Chenevix-Trench G, Antoniou AC, Ottini L (2016) Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the consortium of investigators of modifiers of BRCA1/2. Breast Cancer Res 18(1):15. doi:10.​1186/​s13058-016-0671-y CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Moran A, O’Hara C, Khan S, Shack L, Woodward E, Maher ER, Lalloo F, Evans DG (2012) Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations. Fam Cancer 11(2):235–242. doi:10.1007/s10689-011-9506-2 CrossRefPubMed Moran A, O’Hara C, Khan S, Shack L, Woodward E, Maher ER, Lalloo F, Evans DG (2012) Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations. Fam Cancer 11(2):235–242. doi:10.​1007/​s10689-011-9506-2 CrossRefPubMed
11.
Zurück zum Zitat Maatta K, Rantapero T, Lindstrom A, Nykter M, Kankuri-Tammilehto M, Laasanen SL, Schleutker J (2016) Whole-exome sequencing of finnish hereditary breast cancer families. Eur J Hum Genet 25(1):85–93. doi:10.1038/ejhg.2016.141 CrossRefPubMed Maatta K, Rantapero T, Lindstrom A, Nykter M, Kankuri-Tammilehto M, Laasanen SL, Schleutker J (2016) Whole-exome sequencing of finnish hereditary breast cancer families. Eur J Hum Genet 25(1):85–93. doi:10.​1038/​ejhg.​2016.​141 CrossRefPubMed
13.
Zurück zum Zitat Hemminki K, Ji J, Brandt A, Mousavi SM, Sundquist J (2010) The Swedish Family-Cancer Database 2009: prospects for histology-specific and immigrant studies. Int J Cancer 126:2259–2267. doi:10.1002/ijc.24795 PubMed Hemminki K, Ji J, Brandt A, Mousavi SM, Sundquist J (2010) The Swedish Family-Cancer Database 2009: prospects for histology-specific and immigrant studies. Int J Cancer 126:2259–2267. doi:10.​1002/​ijc.​24795 PubMed
15.
Zurück zum Zitat zur Hausen H (2002) Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2:342–350CrossRefPubMed zur Hausen H (2002) Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2:342–350CrossRefPubMed
16.
Zurück zum Zitat Hussain SK, Sundquist J, Hemminki K (2008) Familial clustering of cancer at human papillomavirus-associated sites according to the Swedish Family-Cancer Database. Int J Cancer 122(8):1873–1878. doi:10.1002/ijc.23265 CrossRefPubMed Hussain SK, Sundquist J, Hemminki K (2008) Familial clustering of cancer at human papillomavirus-associated sites according to the Swedish Family-Cancer Database. Int J Cancer 122(8):1873–1878. doi:10.​1002/​ijc.​23265 CrossRefPubMed
18.
Zurück zum Zitat Hemminki K, Ji J, Sundquist J, Shu X (2011) Familial risks in cancer of unknown primary: tracking the primary sites. J Clin Oncol 29:435–440CrossRefPubMed Hemminki K, Ji J, Sundquist J, Shu X (2011) Familial risks in cancer of unknown primary: tracking the primary sites. J Clin Oncol 29:435–440CrossRefPubMed
19.
Zurück zum Zitat Naslund-Koch C, Nordestgaard BG, Bojesen SE (2016) Increased risk for other cancers in addition to breast cancer for CHEK2*1100delC Heterozygotes estimated from the copenhagen general population study. J Clin Oncol 34(11):1208–1216. doi:10.1200/jco.2015.63.3594 CrossRefPubMed Naslund-Koch C, Nordestgaard BG, Bojesen SE (2016) Increased risk for other cancers in addition to breast cancer for CHEK2*1100delC Heterozygotes estimated from the copenhagen general population study. J Clin Oncol 34(11):1208–1216. doi:10.​1200/​jco.​2015.​63.​3594 CrossRefPubMed
20.
Zurück zum Zitat Yu H, Frank C, Sundquist J, Hemminki A, Hemminki K (2017) Common cancers share familial susceptibility: implications for cancer genetics and counselling. J Med Genet. doi:10.1136/jmedgenet-2016-103932 Yu H, Frank C, Sundquist J, Hemminki A, Hemminki K (2017) Common cancers share familial susceptibility: implications for cancer genetics and counselling. J Med Genet. doi:10.​1136/​jmedgenet-2016-103932
23.
Zurück zum Zitat Frank C, Sundquist J, Yu H, Hemminki A, Hemminki K (2017) Concordant and discordant familial cancer: familial risks, proportions and population impact. Int J Cancer 140:1510–1516CrossRefPubMed Frank C, Sundquist J, Yu H, Hemminki A, Hemminki K (2017) Concordant and discordant familial cancer: familial risks, proportions and population impact. Int J Cancer 140:1510–1516CrossRefPubMed
Metadaten
Titel
Familial associations of male breast cancer with other cancers
verfasst von
Guoqiao Zheng
Hongyao Yu
Akseli Hemminki
Asta Försti
Kristina Sundquist
Kari Hemminki
Publikationsdatum
23.08.2017
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 3/2017
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-017-4468-1

Weitere Artikel der Ausgabe 3/2017

Breast Cancer Research and Treatment 3/2017 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.